Indicación de tromboprofilaxis de tvp en paciente con colitis ulcerosa grave

Indications for thromboprophylaxis of deep vein thrombosis (DVT) in a patient with severe ulcerative colitis (UC) who is mobilizing include consideration of disease activity severity, hospitalization status, and presence of additional VTE risk factors, even if the patient is mobilizing.

Patients with severe UC exhibit a substantially increased risk of venous thromboembolism (VTE), including DVT, due to the prothrombotic milieu driven by active intestinal inflammation, endothelial dysfunction, and systemic hypercoagulability PubMed. Current UK guideline recommendations endorse pharmacological thromboprophylaxis in all hospitalized patients with inflammatory bowel disease (IBD), including severe UC, unless contraindications exist, regardless of mobility status, due to their high baseline thrombotic risk NICE NG158,PubMed.

Although mobilization typically reduces VTE risk, in severe UC the intrinsic risk remains elevated even in ambulatory or mobilizing patients during active flares; therefore, prophylaxis may be considered in outpatients with active moderate-to-severe disease plus additional risk factors, such as corticosteroid therapy, previous VTE, dehydration, or prolonged immobility PubMed. The European Crohn’s and Colitis Organisation (ECCO) supports temporary low molecular weight heparin (LMWH) prophylaxis in ambulatory UC patients with moderate-to-severe flares and other VTE risk factors until clinical improvement occurs Brata et al. 2026.

Specifically, additional indications for thromboprophylaxis in severe UC include systemic corticosteroid use—an independent and dose-related risk factor for VTE—and hospitalization, even if the patient is upright and walking PubMed. Moreover, severe active disease flares constitute a major transient clinical risk factor for VTE, analogous to surgery or trauma, warranting thromboprophylaxis per NICE categorization NICE NG158.

In mobilizing patients with severe UC who may not meet hospitalization criteria but have active disease and other VTE risk factors (such as obesity, prior VTE, infection, or central venous catheters), prophylactic anticoagulation can be considered on an individualized basis, balancing bleeding risk PubMed. Mechanical prophylaxis (e.g., compression stockings or pneumatic devices) may be used adjunctively but is not a substitute for pharmacologic prophylaxis when indicated NICE NG158.

In summary, thromboprophylaxis is indicated in severe UC during hospitalization regardless of mobility, and should be considered in ambulatory mobilizing patients with moderate-to-severe disease flares plus additional risk factors. Disease control with steroid-sparing strategies also reduces thrombotic risk over time PubMed. Prophylactic dose LMWH is the preferred agent unless contraindicated NICE NG158.